• Elite Pharmaceuticals posted net income attributable to common shareholders of $44.9 million, swinging from a loss, as revenue rose 77% to $148.9 million.
• Operating income climbed to $49.1 million from $19.6 million as gross margin widened 2 percentage points to 50%.
• General and administrative expense jumped 95% to $17.6 million; total operating expenses increased 26% to $25.9 million.
• Other income turned positive at $7.7 million, driven by a $7.86 million gain from changes in warrant derivative fair value.
• Announced an April 2, 2026 launch of generic methadone tablets; filed a June 1, 2026 ANDA for an undisclosed anticoagulant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031070), on June 29, 2026, and is solely responsible for the information contained therein.